About Oramed
Oramed is a publicly listed company based in Jerusalem (Israel) founded in 2006. Oral reformulations for health conditions are developed using proprietary technology. The company has 13 employees. Oramed offers products and services including ORMD-0801 and ORMD-0901. Its focus areas include Life Sciences, Diabetes, Drugs and Drug Delivery. Its legal entity is Oramed Pharmaceuticals, Inc.
Company details
Oramed was founded in 2006 in Jerusalem, Israel, and operates in the biotechnology sector focused on oral drug delivery. Proprietary POD technology is utilized to shield proteins from gastrointestinal enzymatic degradation and enhance intestinal absorption. The pipeline features ORMD-0801, targeted at type-2 and type-1 diabetes, along with an oral version of Exenatide, a glucagon-like peptide-1 analog designed to promote insulin secretion.
- Headquarters Jerusalem, Israel
- Employees 13
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website oramed.com
- Social LinkedIn X Facebook YouTube
- Legal Name Oramed Pharmaceuticals Inc.
- Annual Revenue$2 M (USD)as on Dec 31, 2025
- Net Profit$63.24 M (USD)as on Dec 31, 2025
- EBITDA-$14.97 M (USD)-18.9as on Dec 31, 2025
- Latest Funding Round$55.29K (USD), Grant
Mar 2020
- InvestorsEuropean Union
& 1 more
- Employee Count13
Products & Services of Oramed
Oramed offers a comprehensive portfolio of products and services, including ORMD-0801 and ORMD-0901.
Oral capsule for treating diabetes and NASH conditions
Oral therapy for metabolic disorders like diabetes
Apps and channels of Oramed
its YouTube channel Oramed Pharmaceuticals has 595 subscribers and 30 videos.
Videos from Oramed
The most watched videos on Oramed's YouTube channel, Oramed Pharmaceuticals (595 subscribers). Click a video to play it here.
More on Oramed Pharmaceuticals.
Funding Insights of Oramed
- Total Rounds 6
- Last Round Grant — $55,285
- First Round $3.36M
(Apr 2011)
- Investors Count 2
All 6 funding rounds of Oramed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $55,285 | Grant | – | – | |
| Dec 2019 | $55,095 | Grant | – | – | |
| Jul 2018 | $18.1M | Post-IPO | – | – | – |
| Jan 2013 | $76,360 | Post-IPO | – | – | – |
| Sep 2012 | $1M | Post-IPO | – | – | – |
| Apr 2011 | $3.36M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Oramed
Oramed has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Oramed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Oramed
18 people are tracked at Oramed (5 in leadership, 12 in board & advisors, 1 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Josh Hexter | Chief Operating & Business Officer | Leadership |
Miriam Kidron | Chief Scientific Officer & Director | Leadership |
Nadav Kidron | CEO, President & Director | Leadership |
Bruce Francis | VP | Leadership |
Estee Yaari | Director Of Corporate Communications | Leadership |
Alexander Fleming | Scientific Advisor | Board & advisors |
Ele Ferrannini | Scientific Advisor | Board & advisors |
Leonard Sank | Director | Board & advisors |
Arie Mayer | Director | Board & advisors |
Julio Rosenstock | Scientific Advisor | Board & advisors |
Roy Eldor | Scientific Advisor | Board & advisors |
Jay Skyler | Scientific Advisor | Board & advisors |
Avram Hershko | Scientific Advisor | Board & advisors |
Harold Jacob | Scientific Advisor | Board & advisors |
Anne Peters | Scientific Advisor | Board & advisors |
Yadin Rozov | Director | Board & advisors |
Ben Shapiro | Director | Board & advisors |
Hillel Steiner | Financial Controller | Team |
Complete people profiles for Oramed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Oramed
Oramed is a publicly listed company on the NASDAQ with ticker symbol ORMP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Feb 2013
- Listed onNASDAQ: ORMP
- Listed entityOramed Pharmaceuticals Inc.
- Exchange sectorHealth technology
- ISINUS68403P2039
- Share price$4.17 (-2.34% on the day) · 2026-10-13
- Market capitalisation$173.5M
- Price to earnings1.0
- EPS (diluted, trailing year)$4.11
- Volume (last session)113,751
Financials of Oramed
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.0M | $63.2M | -$15.0M |
| 2024 | -$19.1M | -$12.6M | |
| 2023 | $1.3M | $5.5M | -$15.6M |
| 2022 | $2.7M | -$36.6M | -$40.5M |
| 2021 | $2.7M | -$22.2M | -$23.1M |
Detailed financial statements for Oramed
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Oramed
4 dated milestones of Oramed across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Oramed is founded.
- Funding First funding round of $3.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $55K.
Web traffic of Oramed
The website of Oramed (oramed.com) receives about 4K visits a month and ranks #6,529,382 among all websites worldwide, #6,622 in Biotechnology and Pharmaceuticals.
- Monthly visits4K
▲ 55% vs previous month
- Unique visitors1.1K
per month
- Global rank#6,529,382
among all websites
- Category rank#6,622
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.6
- Average visit27 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Oramed. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| amneal.com | 100% | 26.8K | #959,075 | View details | |
accesspharma.com | accesspharma.com | 100% | – | ||
| deciphera.com | 98% | 12.2K | #2,044,202 | View details | |
| emisphere.com | 98% | View details | |||
kspico.net | kspico.net | 98% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Oramed
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oramed
Complete news archive for Oramed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oramed
Oramed was founded in 2006 and raised its 1st funding round 5 years after it was founded.
Oramed is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
Oramed has 13 employees.
Annual revenue of Oramed is $2M as on Dec 31, 2025.
Oramed was founded in 2006 in Jerusalem, Israel, and operates in the biotechnology sector focused on oral drug delivery. Proprietary POD technology is utilized to shield proteins from gastrointestinal enzymatic degradation and enhance intestinal absorption. The pipeline features ORMD-0801, targeted at type-2 and type-1 diabetes, along with an oral version of Exenatide, a glucagon-like peptide-1 analog designed to promote insulin secretion.
Oramed offers ORMD-0801 and ORMD-0901.
Yes, Oramed is publicly traded on NASDAQ under the ticker symbol ORMP.
Oramed has 2 investors. Key investors include European Union, and EIC Fund.
Oramed operates through Oramed Pharmaceuticals, Inc..